DCRI-collaboration-empact-mi
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of p...
Source: Boehringer Ingelheim Corporate News - May 26, 2020 Category: Research Source Type: news
Call for More Transparency in Gray Area of Post-Approval Drug Studies Call for More Transparency in Gray Area of Post-Approval Drug Studies
' Post-market safety studies are often inadequate, not completed, and poorly reported in the public arena, ' say the authors of study examining SGLT2 inhibitors. But clinicians say this is not so black and white.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors May Prevent Diabetic Kidney Disease SGLT2 Inhibitors May Prevent Diabetic Kidney Disease
Patients with type 2 diabetes in real-world practice who received an SGLT2 inhibitor rather than a DPP-4 inhibitor were less likely to develop serious renal events, consistent with clinical trial findings.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 4, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors Linked to Reduced Risk for Serious Renal Events
FRIDAY, May 1, 2020 -- Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk for serious renal events compared with dipeptidyl peptidase-4 inhibitors, according to a study published online April 29 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2020 Category: Pharmaceuticals Source Type: news
Sodium-Glucose Transporter-2 Inhibition: An Important Advancement for...
In this free webinar, the speakers will review SGLT2 inhibitors and present emerging data on SGLT2 inhibitors and the impact on patients with type 2 DM and CKD.(PRWeb March 23, 2020)Read the full story at https://www.prweb.com/releases/sodium_glucose_transporter_2_inhibition_an_important_advancement_for_patients_with_type_2_diabetes_and_chronic_kidney_disease_upcoming_webinar_hosted_by_xtalks/prweb16996158.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 23, 2020 Category: Pharmaceuticals Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
A U.S. Food and Drug Administration (FDA) safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 19, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Says Stop SGLT2 Inhibitors for Diabetes Prior to Surgery FDA Says Stop SGLT2 Inhibitors for Diabetes Prior to Surgery
Label changes were approved by the FDA as surgery may put patients being treated with SGLT2 inhibitors at higher risk of ketoacidosis.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - March 18, 2020 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news
Renal Effects of SGLT2 Inhibitors: An Update Renal Effects of SGLT2 Inhibitors: An Update
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes, but what do we know about the renal effects of these drugs?Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 19, 2020 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
A New Perspective on Lowering CV Risk From Hypoglycemia A New Perspective on Lowering CV Risk From Hypoglycemia
A new study explores the relationship between hypoglycemia, cardiovascular outcomes, and treatment with an SGLT2 inhibitor. Might an SGLT2 inhibitor offer a cardio-protective effect?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 12, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
SGLT2 Inhibition: A New Avenue to Protect the Kidney SGLT2 Inhibition: A New Avenue to Protect the Kidney
Could SGLT2 inhibitors have a role in the management of patients with kidney disease? What are the benefits of these agents?Nephrology Dialysis Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 12, 2020 Category: Surgery Tags: Nephrology Journal Article Source Type: news
SGLT2 Inhibitors: Searching for Mechanisms SGLT2 Inhibitors: Searching for Mechanisms
Recent trials are exploring the role of SGLT2 inhibitors in cardiovascular disease, highlighting their clinical utility beyond diabetes. But their mechanism of cardiac effects remains unclear.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
SGLT2 Inhibitors Risky in Latent Autoimmune Diabetes SGLT2 Inhibitors Risky in Latent Autoimmune Diabetes
Sodium-glucose co-transporter-2 (SGLT2) inhibitors can cause ketoacidosis in patients with latent autoimmune diabetes (LADA), a report on three cases in the American Journal of Medicine confirms.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 22, 2020 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news
Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report - Nakamura M, Nakade J, Toyama T, Okajima M, Taniguchi T.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit SGLT2, which is expressed in the proximal renal tubule, and thus reduce blood glucose levels by enabling the urinary excretion of excess glucose. SGLT2 inhibitors have been reported to s... (Source: SafetyLit)
Source: SafetyLit - January 14, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Diabetes Drug Class May Hold Promise for Gout Prevention Diabetes Drug Class May Hold Promise for Gout Prevention
Adults with type 2 diabetes prescribed an SGLT2 inhibitor were less likely to develop gout than those prescribed a GLP-1 receptor agonist.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - January 13, 2020 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news
